3,75 $
0,53 % gestern
Nasdaq, 5. Dezember, 22:00 Uhr
ISIN
US51654W1018
Symbol
LTRN
Berichte
Quartal | Jahr
Index
NASDAQ Composite
Sektor
Pharma, Biotechnologie und Life Sciences
Industrie
Biotechnologie
Mit Parqet Logo tracken

Lantern Pharma Inc Aktie News

Neutral
Business Wire
●
3 Tage alt
Lantern Pharma Reports Additional Positive LP-184 Phase 1a Results Showing Durable Disease Control in Heavily Pre-Treated Advanced Cancer Patients as Company Advances Precision Oncology Program into Multiple Biomarker-Guided Phase 1b/2 Trials
DALLAS--(BUSINESS WIRE)--LP-184 Clinical Insights, KOL Webinar & Future Plans.
Positiv
Finbold
●
13 Tage alt
2 sub‑$10 AI stocks to outperform Palantir in 2026, according to ChatGPT‑5
Palantir Technologies (NASDAQ: PLTR) has grown into a dominant force in AI-driven data analytics, securing lucrative government contracts and expanding its mission-critical intelligence business.
Neutral
Seeking Alpha
●
16 Tage alt
Lantern Pharma Inc. (LTRN) Discusses LP-184 Phase 1a Clinical Results and Implications for DNA Damage Repair-Deficient Tumors Transcript
Lantern Pharma Inc. ( LTRN ) Discusses LP-184 Phase 1a Clinical Results and Implications for DNA Damage Repair-Deficient Tumors November 20, 2025 4:30 PM EST Company Participants Panna Sharma - President, CEO & Director Kishor Bhatia - Chief Scientific Officer & Scientific Consultant Reggie Ewesuedo Conference Call Participants Igor Astsaturov Presentation Panna Sharma President, CEO & Director...
Neutral
Seeking Alpha
●
23 Tage alt
Lantern Pharma Inc. (LTRN) Q3 2025 Earnings Call Transcript
Lantern Pharma Inc. ( LTRN ) Q3 2025 Earnings Call November 13, 2025 9:00 AM EST Company Participants Panna Sharma - President, CEO & Director David Margrave - CFO & Secretary Presentation Operator Good morning, and welcome to our third quarter 2025 earnings call. As a reminder, this call is being recorded [Operator Instructions].
Neutral
Business Wire
●
23 Tage alt
Lantern Pharma Reports Third Quarter 2025 Financial Results and Provides Business Updates
DALLAS--(BUSINESS WIRE)--Q3 Press Release - BTM.
Neutral
Business Wire
●
etwa ein Monat alt
Lantern Pharma to Report Third Quarter 2025 Operating & Financial Results on November 13th, 2025 at 9:00 a.m. ET
DALLAS--(BUSINESS WIRE)--Lantern Pharma to Report Third Quarter 2025 Operating & Financial Results on November 13th, 2025 at 9:00 a.m. ET.
Neutral
Business Wire
●
etwa ein Monat alt
Lantern Pharma to Present AI-Driven Cancer Drug Development & Research Platforms at Inaugural AI for Biology and Medicine Symposium at UNT
DALLAS--(BUSINESS WIRE)--Lantern Pharma to Present AI-Driven Cancer Drug Development & Research Platforms at Inaugural AI for Biology and Medicine Symposium at UNT.
Neutral
Business Wire
●
etwa ein Monat alt
Lantern Pharma Presents LP-284 Clinical Data at 25th LL&M Congress, Highlighting Complete Response in Therapeutically Exhausted DLBCL Patient & Therapeutic Potential in Advanced B-Cell Cancers.
DALLAS--(BUSINESS WIRE)--LP-284 at 25th LL&M Congress & CMR.

Kostenlos registrieren

aktien.guide ist das Tool zum einfachen Finden, Analysieren und Beobachten von Aktien. Lerne von erfolgreichen Investoren und triff fundierte Anlageentscheidungen. Wir machen Dich zum selbstbestimmten Investor.

Jetzt starten
Die Apple Aktie im Überblick mit Charts, aktuellen Kennzahlen, Nachrichten und Aktienanalysen.
Die besten Dividenden-Aktien in der Dividenden-Topscorer-Liste.
Aktienanalysen der besten Aktien weltweit.
Jetzt Vermögen aufbauen